All In Biotech

NDA 019970 · Baxter Hlthcare

Nitroglycerin In Dextrose 5%

Nitroglycerin · Injection · Nitrate Vasodilator

Last checked: Nov 20, 2026Latest source record: Aug 22, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1989

Dec 29, 1989

Approved uses

1

Original approval plus efficacy supplements

Registered trials

237

47 Phase 3, 10 recruiting

FAERS reports

40,398

32,851 serious, 5,402 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 18, 2025.

INDICATIONS AND USAGE Nitroglycerin in 5% Dextrose Injection is indicated for treatment of peri-operative hypertension; for control of heart failure in the setting of acute myocardial infarction; for treatment of angina pectoris in patients who have not responded to sublingual nitroglycerin and ß-blockers; and for induction of intraoperative hypotension.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 29, 1989 Original approval · Type 3 - New Dosage Form
3 products under this application
  • NITROGLYCERIN IN DEXTROSE 5% · NITROGLYCERIN 20MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • NITROGLYCERIN IN DEXTROSE 5% · NITROGLYCERIN 40MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • NITROGLYCERIN IN DEXTROSE 5% · NITROGLYCERIN 10MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Nitroglycerin" as an intervention, any sponsor and status, largest first.

All 237 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea3,466
  • pain3,149
  • fatigue2,783
  • myocardial infarction2,706
  • nausea2,666
  • fall2,439
  • chest pain2,400
  • dizziness2,392
  • drug ineffective2,367
  • headache2,197
  • diarrhoea2,135
  • hypotension2,026

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004946
20051,063
2006899
2007676
2008900
20091,201
20101,366
20112,238
20121,664
2013816
20142,369
20151,411
20161,613
20171,694
20182,072
20192,228
20202,076
20212,216
20222,851
20232,837
20242,792
20252,688
20261,778

Recalls

1 FDA enforcement reports for this application.

  • Nov 18, 2013 · Class I · Terminated

    Presence of Particulate Matter; particulate matter in one vial identified as silicone rubber and EPDM rubber from the vial stopper.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,056 on PubMed

Sponsor: Baxter Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.